Analysts Set Tempus AI, Inc. (NASDAQ:TEM) PT at $84.00

Tempus AI, Inc. (NASDAQ:TEM) has been given a consensus recommendation of “Hold” by the fourteen brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $87.20.

Several equities research analysts recently weighed in on the stock. Piper Sandler cut their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Guggenheim boosted their target price on shares of Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, September 26th. JPMorgan Chase & Co. cut their price target on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Finally, HC Wainwright lowered their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research report on Friday, November 7th.

Tempus AI Trading Up 2.0%

Shares of NASDAQ:TEM opened at $70.33 on Friday. The business’s 50 day simple moving average is $69.17 and its 200 day simple moving average is $73.41. Tempus AI has a 1 year low of $34.35 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The company has a market capitalization of $12.51 billion, a P/E ratio of -59.10 and a beta of 5.22.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company’s quarterly revenue was up 84.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.46) EPS. On average, research analysts anticipate that Tempus AI will post -6.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Eric P. Lefkofsky sold 332,500 shares of the business’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $89.11, for a total transaction of $29,629,075.00. Following the completion of the transaction, the chief executive officer owned 9,074,532 shares of the company’s stock, valued at approximately $808,631,546.52. The trade was a 3.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Ryan Fukushima sold 10,099 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $65.54, for a total value of $661,888.46. Following the completion of the sale, the chief operating officer directly owned 829,081 shares in the company, valued at $54,337,968.74. This trade represents a 1.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 932,832 shares of company stock worth $71,184,024. 26.27% of the stock is currently owned by company insiders.

Institutional Trading of Tempus AI

Hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. lifted its position in shares of Tempus AI by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after purchasing an additional 162 shares during the period. Global Retirement Partners LLC raised its stake in Tempus AI by 29.5% during the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock worth $59,000 after buying an additional 167 shares during the last quarter. US Bancorp DE lifted its holdings in Tempus AI by 6.6% in the third quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after buying an additional 176 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Tempus AI by 0.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company’s stock valued at $2,145,000 after acquiring an additional 226 shares during the last quarter. Finally, SeaCrest Wealth Management LLC grew its holdings in Tempus AI by 3.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock worth $524,000 after acquiring an additional 229 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.